Quarterly Result4 Aug 2026, 02:21 pm
Alembic Pharma Q1 FY27 Revenue Up 26% to ₹2150 Cr
AI Summary
Alembic Pharmaceuticals reported a resilient Q1 FY27 performance with consolidated revenue from operations increasing by 26% year-on-year to ₹2150 Cr. Profit After Tax grew 12% YoY to ₹173 Cr, and EBITDA pre-R&D stood at ₹523 Cr, with a margin of 24%. The company saw strong growth across its businesses, particularly in the US formulation segment, which grew by 49% to ₹778 Cr. The India Branded Business also contributed positively with 7% YoY growth, reaching ₹642 Cr. Alembic Pharmaceuticals launched 3 new products in India and 7 in the US during the quarter, alongside receiving 10 ANDA approvals. The API business grew by 33% to ₹346 Cr.
Key Highlights
- Q1 FY27 revenue surged 26% YoY to ₹2150 Cr.
- US Formulation business showed strong growth of 49% YoY.
- India Branded Business grew 7% YoY, driven by key segments.
- API business expanded by 33% YoY.
- Company launched multiple new products across markets.
Price Impact
More from APLLTD